Skip to main navigation Skip to search Skip to main content

Molecular diagnostics in the management of rhabdomyosarcoma

  • Michael A. Arnold
  • , Fredric G. Barr

Research output: Contribution to journal › Review article › peer-review

Abstract

Introduction: A classification of rhabdomyosarcoma (RMS) with prognostic relevance has primarily relied on clinical features and histologic classification as either embryonal or alveolar RMS. The PAX3-FOXO1 and PAX7-FOXO1 gene fusions occur in 80% of cases with the alveolar subtype and are more predictive of outcome than histologic classification. Identifying additional molecular hallmarks that further subclassify RMS is an active area of research. Areas Covered: The authors review the current state of the PAX3-FOXO1 and PAX7-FOXO1 fusions as prognostic biomarkers. Emerging biomarkers, including mRNA expression profiling, MYOD1 mutations, RAS pathway mutations and gene fusions involving NCOA2 or VGLL2 are also reviewed. Expert commentary: Strategies for modifying RMS risk stratification based on molecular biomarkers are emerging with the potential to transform the clinical management of RMS, ultimately improving patient outcomes by tailoring therapy to predicted patient risk and identifying targets for novel therapies.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalExpert Review of Molecular Diagnostics
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • FGFR4
  • MYOD1
  • NCOA2
  • RAS
  • Rhabdomyosarcoma
  • VGLL2
  • fusion oncogene
  • gene amplification
  • molecular testing
  • risk stratification

Fingerprint

Dive into the research topics of 'Molecular diagnostics in the management of rhabdomyosarcoma'. Together they form a unique fingerprint.

Cite this